David S. Kinard - Mar 1, 2022 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role
Executive Vice President, Human Resources, Corporate Affairs and Administration
Signature
/s/ Collin G. Smyser, Attorney-in-Fact for David S. Kinard
Stock symbol
ELAN
Transactions as of
Mar 1, 2022
Transactions value $
-$75,239
Form type
4
Date filed
3/3/2022, 08:01 PM
Previous filing
Feb 24, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELAN Common Stock Award $0 +8.67K +9.78% $0.00 97.2K Mar 1, 2022 Direct F1
transaction ELAN Common Stock Tax liability -$49.9K -1.72K -1.77% $28.94 95.5K Mar 1, 2022 Direct F2
transaction ELAN Common Stock Tax liability -$25.3K -874 -0.92% $29.00 94.6K Mar 2, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELAN Employee Stock Option(right to buy) Award $0 +23K $0.00 23K Mar 1, 2022 Common Stock 23K $28.94 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units pursuant to the Amended and Restated 2018 Elanco Stock Plan on March 1, 2022, one-third vesting on March 1, 2023, one-third vesting on March 1, 2024, and the remaining vesting on March 1, 2025.
F2 Represents shares tendered to the Company to cover the Reporting Person's tax liability upon vesting of restricted stock units previously awarded under the Amended and Restated 2018 Elanco Stock Plan
F3 Grant of stock options vesting as follows: one-third vesting on March 1, 2023, one-third vesting on March 1, 2024, and the remaining vesting on March 1, 2025.

Remarks:

Executive Vice President, Human Resources, Corporate Affairs and Administration